The short version of research chemical fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-02 and is reviewed periodically as new material appears.
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.
Lyophilised peptide powder is comparatively stable when kept dry, cold and protected from light. Once dissolved, the molecule is exposed to hydrolysis, oxidation and microbial growth, and degradation accelerates at higher temperatures and in alkaline solution. Repeated freeze-thaw cycles concentrate solutes and promote aggregation. Handling guidance for research peptides commonly clusters around freezer temperatures for powder and short refrigerated use for reconstituted solutions, with pH control and sterile technique applied throughout.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Lyophilised cake or flake |
| Solubility class | Soluble in water and aqueous buffer | Also soluble in some polar organic solvents |
| Typical storage temperature | Minus 20 degrees Celsius or below | Desiccated and protected from light |
| Typical analytical method | LC-MS/MS | Reversed-phase separation with mass detection |
| Molecular formula | C50H69N15O9 | Free base; salt forms differ |
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Hemp juice is produced in a patented industrial procedure directly following harvest whereby the leafy upper part of the plant, including the flower heads, are being cold-pressed after harvest. These parts of the hemp plant have been entirely neglected so far in industrial hemp fabric production. Hence, through the procedure of pressing juice, a previously neglected highly valuable part of the plant is now being used for human consumption. All active ingredients remain fully intact without drying the hemp. The juice does not compete with the production of fibers and shives instead both add up to double revenue of the farmer. The average yield of hemp juice is approximately 3 tons per hectare. This newly developed production procedure allows for a significantly higher financial efficiency as well as sustainability in the cultivation of drug-free industrial hemp. Furthermore, the cold-pressing procedure preserves all of the plant-based active ingredients. There are two common harvesting procedures: "Cutting" the upper parts of the hemp plant or "stripping" the leaves off the uppermost part of the hemp plant. Both these procedures result in varying quantities of cannabinoids in the hemp juice. Consequently, the harvesting procedure in itself already influences the quality of the resulting hemp juice. If one only uses the uppermost, leafy part of the hemp plant for hemp juice production, the remaining part of the hemp plant can still be used for the industrial production of its fibers or any other industrial uses.
===== MeSH D08.811.464.267 – carbon-sulfur ligases (EC 6.2) ===== MeSH D08.811.464.267.500 – coenzyme a ligases MeSH D08.811.464.267.500.200 – acetate-coa ligase MeSH D08.811.464.267.500.600 – succinate-coa ligases
=== Distance restraints === A crosspeak in a NOESY experiment signifies spatial proximity between the two nuclei in question. Thus each peak can be converted into a maximum distance between the nuclei, usually between 1.8 and 6 angstroms. The intensity of a NOESY peak is proportional to the distance to the minus 6th power, so the distance is determined according to the intensity of the peak. The intensity-distance relationship is not exact, so usually a distance range is used. It is important to assign the NOESY peaks to the correct nuclei based on the chemical shifts. If this task is performed manually, it is usually very labor-intensive since proteins usually have thousands of NOESY peaks. Some computer programs such as PASD/XPLOR-NIH, UNIO, CYANA, ARIA/CNS, and AUDANA/PONDEROSA-C/S in the Integrative NMR platform perform this task automatically on manually pre-processed listings of peak positions and peak volumes, coupled to a structure calculation. Direct access to the raw NOESY data without the cumbersome need of iteratively refined peak lists is so far only granted by the PASD algorithm implemented in XPLOR-NIH, the ATNOS/CANDID approach implemented in the UNIO software package, and the PONDEROSA-C/S and thus indeed guarantees objective and efficient NOESY spectral analysis. To obtain as accurate assignments as possible, it is a great advantage to have access to carbon-13 and nitrogen-15 NOESY experiments, since they help to resolve overlap in the proton dimension. This leads to faster and more reliable assignments, and in turn to better structures.
LEDs are used in mining operations, as cap lamps to provide light for miners. Research has been done to improve LEDs for mining, to reduce glare and to increase illumination, reducing risk of injury to the miners. LEDs are increasingly finding uses in medical and educational applications, for example as mood enhancement. NASA has even sponsored research for the use of LEDs to promote health for astronauts.
Sources: en.wikipedia.org
Since both compounds are in the same solution and are injected together, the volume terms are equal and cancel out. The above equation is then rearranged to solve for the ratio of the k's. This ratio is then called the response factor, F.
==== Expressive therapies ==== Expressive therapies or creative arts therapies are a form of psychotherapy that involves the arts or artmaking. These therapies include art therapy, music therapy, drama therapy, dance therapy, and poetry therapy. It has been proven that music therapy is an effective way of helping people with a mental health disorder. Drama therapy is approved by NICE for the treatment of psychosis.
=== Anthropology and Race === In developing his psychological theories, Jung extensively studied the anthropological and ethnographic field work available to him at the time. This aspect of his work has become contentious and has spawned a significant body of scholarship. Some scholars argue that the anthropological theories that Jung relied on, as well as Jung's thinking itself, are implicated in colonial and racist conceptions of Indigenous and pre-modern cultures in which they were constructed as inferior to Europeans. Others have argued that such an approach oversimplifies both early anthropology as well as Jung's use of it, and that as a consequence Jung's anthropological thought retains relevance for contemporary evolutionary conceptions of the human mind. For example, Jung drew heavily on the ethnographic field work of Spencer and Gillen, who from 1896 to 1903 undertook extensive field work amongst the Arrernte people of Central Australia. While Spencer and Gillen's works were influenced by the surrounding prejudices of colonial culture, they also enabled the broader community to understand Indigenous culture and thereby help overcome those prejudices, understanding that continues to the present particularly in the relevance of their research to contemporary anthropology. Given the contemporary relevance of Spencer and Gillen's field work, particularly in relation to the Indigenous concept of the Dreaming, it has been argued that Jung's theories retain their relevance.
Sources: en.wikipedia.org
Mass spectrometry combined with liquid chromatography provides both molecular weight confirmation and a measure of related impurities. Tandem mass spectrometry adds sequence information. A purity percentage reported without a mass measurement does not confirm what the material is.
No. Lyophilisation slows degradation rather than stopping it, and the rate depends on residual moisture, temperature and light exposure. Freezer storage extends useful life but does not make the material permanent.
A certificate is only as good as its traceability to a specific batch and a named laboratory. Documents lacking batch numbers, method descriptions or laboratory identifiers carry little weight. Confirming what was actually received generally requires a separate test of the material in hand.
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.